- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03800914
High Intensity Interval Training in Fibrotic Interstitial Lung Disease (HIIT in fILD)
High Intensity Interval Training in Fibrotic Interstitial Lung Disease: a Randomized Controlled Trial
The fibrotic interstitial lung diseases (fILD) is a group of debilitating chronic lung conditions that are characterised by scarring of lung tissue, dyspnoea on exertion and significant physical impairment. Exercise training is recommended for people with fILD in improving breathlessness and exercise tolerance. However, despite the best efforts of patients and clinicians, many of those who participate are not attaining its benefits. The current exercise training strategies of moderate intensity continuous training may not be well suited to fILD. High intensity interval training (HIIT), short bouts of high-intensity exercise regularly interspersed with periods of rest or light exercise may be an alternate exercise training option for people with fILD.
The study will determine to whether HIIT is better than the current method of continuous exercise training at moderate intensity in improving exercise tolerance, breathlessness and quality of life in people with fILD. A randomised controlled, assessor blinded trial will be conducted. A total 130 people with fILD will be randomly assigned to moderate intensity continuous training or HIIT. If this trial demonstrates that HIIT is effective, it will provide an exercise training strategy that can readily be implemented in practice that will maximise the outcomes of exercise training for people with fILD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Interstitial lung disease (ILD) is a chronic lung condition characterized by scarring of lung tissue. This stiffening of the lungs impairs breathing and reduces the amount of oxygen being delivered throughout the body limiting the ability to perform daily and physical activity. Around two-thirds of people with ILD have fibrotic ILD (fILD), a type of ILD, which typically has worse impairment and disability than other types of ILD. There is no cure for these conditions, although there are two new pharmacological therapies that slow the decline in lung function in Idiopathic Pulmonary Fibrosis (IPF), the most common type of fILD. These treatments however do not provide improvement in breathlessness, exercise capacity or health-related quality of life (HRQoL).
Exercise training, or Pulmonary Rehabilitation (PR), has shown to be effective at improving exercise tolerance and HRQoL in ILD. The investigators recently demonstrated that, at a group level, exercise training exerts a positive effect across varying subtypes of ILD, including IPF, the most rapidly progressive of all the fILDs. However less than half of those with IPF who undertook the exercise training achieved meaningful improvements in exercise capacity. In addition, a large proportion of people with IPF were unable to keep up with the recommended exercise training level, often due to excessive dyspnoea or desaturation. This suggests the current exercise training strategies used in PR, which were adopted from guidelines for patients with chronic obstructive pulmonary disease (COPD), may not provide the optimal exercise stimuli for fILD. High intensity interval training (HIIT), which is short bouts of high intensity exercise regularly interspersed with periods of rest or light exercise, may be an alternate exercise training option for people with fILD. However, it is unknown whether this kind of exercise training achieves superior benefits to the traditional model of PR.
The aim of this project is to determine whether HIIT is better than the current method of continuous exercise training at moderate intensity, in improving exercise capacity, breathlessness and HRQoL in people with fILD. A total 130 people with fILD will be recruited. The trial will be conducted at four hospital sites across Australia. People who agree to take part in the study will be randomly allocated into two groups. Group 1 will undergo the traditional PR model of moderate intensity continuous exercise training and group 2 will undergo HIIT. Participants in both groups will participate in exercise training twice weekly for eight weeks. The participants will be monitored continuously during exercise by an experienced physiotherapist or exercise physiologist. At the beginning and the end of the eight weeks of exercise training, and six months later, participants will undergo measurements of exercise capacity and health status. This study will determine whether HIIT is effective, providing an important exercise training strategy that can be readily used for people with fILD to achieve positive benefits from PR.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anne Holland
- Phone Number: +61 3 99030214
- Email: anne.holland@monash.edu
Study Contact Backup
- Name: Leona Dowman
- Email: leonadowman@gmail.com
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2050
- Not yet recruiting
- Royal Prince Alfred Hospital
-
-
Queensland
-
Brisbane, Queensland, Australia, 4032
- Not yet recruiting
- Prince Charles Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Health
-
Melbourne, Victoria, Australia, 3004
- Recruiting
- Alfred Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of fibrotic interstitial lung disease (fILD)
- Able to read and speak English
Exclusion Criteria:
- Resting oxygen saturation (SpO2) is < 85%
- Severe pulmonary hypertension (WHO class IV)
- Attendance at Pulmonary rehabilitation (PR) within last 12 months
- Comorbidities which preclude exercise training
- History of syncope on exertion
- Significant cognitive impairment
- Anticipated transplant or death within the duration of the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Intensity Interval Training
Participants will undergo a twice-weekly supervised exercise training program for eight weeks.
Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
|
36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
|
Active Comparator: Traditional pulmonary rehabilitation
Participants will undergo a twice-weekly supervised exercise training program for eight weeks.
Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
|
30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in endurance time
Time Frame: Baseline, nine weeks and 6 months following intervention
|
Endurance time measured during constant work rate test (CWRT) at 75% of the peak work rate achieved on a baseline cardiopulmonary exercise test (CPET).
|
Baseline, nine weeks and 6 months following intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in dyspnea measured using the Dyspnea-12 questionnaire
Time Frame: Baseline, nine weeks and 6 months following intervention
|
Dyspnea-12 is a uni-dimensional 12-item questionnaire divided in 2 domains: physical items (1 to 7) and affective items (8-12).
Each item evaluate breathing experience and can be scored as: None (0), Mild (1), Moderate (2) or Severe (3).
Results of this questionnaire will be reported as total score that can range from 0 to 36 and separate scores that can range from 0 to 21 for physical component and 0 to 15 for affective component.
Higher scores indicate worse dyspnea.
|
Baseline, nine weeks and 6 months following intervention
|
Changes in fatigue evaluated by the Fatigue Severity Scale
Time Frame: Baseline, nine weeks and 6 months following intervention
|
Fatigue Severity Scale (FSS), a self reported rating scale including 9 items to measure how fatigue affects motivation, exercise, physical functioning, carrying out duties and how fatigue interferes with work, family, or social life.
Each item is scored on a 7 point scale in which 1 = strongly disagree and 7= strongly agree.
Total score range from 9 to 63.
Higher scores indicate greater fatigue severity.
|
Baseline, nine weeks and 6 months following intervention
|
Change in health related quality of life using the St George's Respiratory Questionnaire idiopathic pulmonary fibrosis specific version (SGRQ-I)
Time Frame: Baseline, nine weeks and 6 months following intervention
|
The SGRQ-I is a disease specific HRQoL measure with similar psychometric properties to the original SGRQ that is designed to be more relevant in patients with IPF.
The questionnaire is divided in 3 domains: Symptoms (frequency and severity), Activity (activities that cause or are limited by breathlessness) and Impact (social functioning and psychological disturbances resulting from airways disease).
Values of each domain as well as the total score value will be reported.
Each item is weighted based on empirical data.
Total score and scores in each domain can range from 0 to 100.
Higher scores indicate more limitations in quality of life.
|
Baseline, nine weeks and 6 months following intervention
|
Change in health related quality of life using the chronic respiratory disease questionnaire (CRQ)
Time Frame: Baseline, nine weeks and 6 months following intervention
|
The CRQ consists of 20 items across 4 domains: Dyspnea (activities that cause breathlessness and are performed frequently), fatigue, emotional function and mastery ( the patient's feeling of control over their disease).
Each domain includes four to seven items, and each item is scored on a 7-point Likert score.
Total scores for each domain range from 4-35.
Values of each domain will be reported.
Lower scores indicate more limitations in quality of life.
|
Baseline, nine weeks and 6 months following intervention
|
Change in anxiety and depression measured by the Hospital Anxiety and Depression Scale
Time Frame: Baseline, nine weeks and 6 months following intervention
|
Hospital Anxiety and Depression Scale (HADS), a scale with 14 items divided into two domains : anxiety symptoms (7 items) and depression symptoms (7 items).
Each item can be scored from 0 to 3. Scores from each domain can vary from 0 to 21 and are stratified as follows: 0-7 (indicates absence of anxiety/depression symptoms); 8-10 ( presence of symptoms of anxiety and depression in moderate degree - borderline); 11 or more (significant number of anxiety/depression symptoms - confirmed cases).
Score of each domain as well as number of confirmed cases will be reported.
|
Baseline, nine weeks and 6 months following intervention
|
Change in functional exercise capacity assessed by 6-minute walk distance
Time Frame: Baseline, nine weeks and 6 months following intervention
|
Distance in meters achieved on a 6-minute walk test
|
Baseline, nine weeks and 6 months following intervention
|
Changes in skeletal muscle size
Time Frame: Baseline, nine weeks and 6 months following intervention
|
Change in cross-sectional area of the Quadriceps will be measured by B-mode ultrasonography
|
Baseline, nine weeks and 6 months following intervention
|
Dyspnea related disability - measured with modified medical research council scale (MMRC)
Time Frame: Baseline, nine weeks and 6 months following intervention
|
The MMRC rates dyspnea according to different levels activity on a 5-point scale (grade 0-4), with grade 4 representing the greatest level of dyspnea impairment.
|
Baseline, nine weeks and 6 months following intervention
|
Global rating of change
Time Frame: Baseline, nine weeks and 6 months following intervention
|
The global rating of change will assess the participants' overall self-perceived change in health by asking the participant to rate their change as either 'worse', 'about the same' or 'better'.
The extent of change ( (i.e., worsening or improvement) is then graded on a Likert scale from one to seven.
|
Baseline, nine weeks and 6 months following intervention
|
Change in physical activity
Time Frame: Baseline, nine weeks and 6 months following intervention
|
Time spent sedentary and in physical activity of various intensities will be measured by a wrist-worn, tri-axial accelerometer.
|
Baseline, nine weeks and 6 months following intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Anne Holland, Monash University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LTU HIIT in ILD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrotic Interstitial Lung Disease
-
University of AlbertaAlberta Boehringer Ingelheim CollaborationNot yet recruitingFibrotic Interstitial Lung Disease
-
University of California, San FranciscoTerminatedFibrotic Interstitial Lung DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingFibrotic Interstitial Lungs DiseasesFrance
-
Mayo ClinicBoehringer IngelheimRecruitingFibrotic Interstitial Lung DiseaseUnited States
-
Monash UniversityRecruitingFibrotic Interstitial Lung DiseaseAustralia
-
Berner Reha Zentrum AGUniversity of Zurich; Zurich University of Applied Sciences; Insel Gruppe AG,...RecruitingQuality of Life | Interstitial Lung Disease | Self Efficacy | Self-management | Patient Education | Fibrotic Lung DiseaseSwitzerland
-
Kingston UniversityUniversity College London Hospitals; St. George's Hospital, LondonCompletedIdiopathic Pulmonary Fibrosis | Interstitial Lung Disease | Chronic Hypersensitivity Pneumonitis | Connective Tissue Related ILD | Fibrotic Lung DiseaseUnited Kingdom
-
King's College Hospital NHS TrustNot yet recruitingBronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Lung Cancer | Interstitial Lung Disease | Chronic Lung Disease | Dyspnea | Fibrotic Lung DiseaseUnited Kingdom
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
Matthias GrieseSuspendedInterstitial Lung Disease | Diffuse Parenchymal Lung Disease | Children´s Interstitial Lung DiseaseGermany
Clinical Trials on High intensity interval training
-
University of MichiganCompletedGlucose IntoleranceUnited States
-
Universidad SurcolombianaMaciste Macias; Gilberto AstaizaRecruiting
-
Kuopio Research Institute of Exercise MedicineKuopio University Hospital; University of Basel; University of Eastern Finland; Social Insurance Institution, FinlandTerminatedUnstable Angina Pectoris | Acute Myocardial Infarction | Recurrent Myocardial InfarctionFinland
-
Cairo UniversityKasr El Aini HospitalCompletedDiabetes Mellitus, Type 2Egypt
-
Universidad Santo TomasCompletedMetabolic DiseasesColombia
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Hunter College of City University of New YorkRecruiting
-
Université de SherbrookeRecruiting
-
Riphah International UniversityCompleted